Table 1 Patient demographics and clinical characteristics

Age at Diagnosis

68 (61–75)

68 (61–75)

68 (61–74)

0.94

Gender

 Male

2838 (55%)

2248 (55%)

590 (54%)

0.33

 Female

2332 (45%)

1821 (45%)

511 (46%)

Race

 Asian

85 (2%)

69 (2%)

16 (1%)

 < 0.001

 Black or African American

433 (8%)

359 (9%)

74 (7%)

-

 White

3593 (69%)

2769 (68%)

824 (75%)

-

 Other

559 (11%)

435 (11%)

124 (11%)

-

 Not Specified

500 (10%)

437 (11%)

63 (6%)

-

ECOG at metastatic diagnosis

 0–1

2779 (54%)

2061 (51%)

718 (65%)

 < 0.001

 2 + 

603 (12%)

493 (12%)

110 (10%)

 Unknown

1788 (35%)

1515 (37%)

273 (25%)

Treatment Received

 Gemcitabine, nab-paclitaxel

2471 (48%)

2018 (50%)

453 (41%)

 < 0.001

 Fluoropyrimidine-based doublet

304 (6%)

160 (4%)

144 (13%)

 FOLFIRINOX

1374 (27%)

1145 (28%)

229 (21%)

 Single-agent cytotoxic chemotherapy

639 (12%)

445 (11%)

194 (18%)

 Non-standard Combination

382 (7%)

301 (7%)

81 (7%)

Stage at diagnosis

 I

106 (2%)

0 (0%)

106 (10%)

 < 0.001

 II

754 (15%)

0 (0%)

754 (68%)

 III

123 (2%)

0 (0%)

123 (11%)

 IV

4069 (79%)

4069 (100%)

0 (0%)

 Unknown

118 (2%)

0 (0%)

118 (11%)

Primary Site

 Body

984 (19%)

878 (22%)

106 (10%)

 < 0.001

 Head

2402 (46%)

1619 (40%)

783 (71%)

-

 Tail

1050 (20%)

913 (22%)

137 (12%)

-

 Overlapping sites

526 (10%)

464 (11%)

62 (6%)

-

 Not specified

208 (4%)

195 (5%)

13 (1%)

-

Smoking Status

 Smoker

2976 (58%)

2342 (58%)

634 (58%)

0.29

 Never smoker

2194 (42%)

1727 (42%)

467 (42%)

-

 Unknown

18 (0%)

17 (0%)

1 (0%)

-

Labs at metastatic diagnosis

 CA19-9 (u/mL)

309.9 (50.7–2769.4)

617 (84–4712)

92.8 (27.8–644.5)

 < 0.001

 Albumin (g/dL)

3.6 (3.2–3.9)

3.6 (3.1–3.9)

3.6 (3.2–4.0)

0.006

 Lymphocytes (× 10⁹/L)

1.3 (0.9–1.8)

1.2 (0.9–1.7)

1.3 (0.9–1.9)

0.05

 Neutrophils (× 10⁹/L)

4.1 (2.5–6.8)

4.2 (2.5- 7.1)

3.9 (2.5- 6.2)

0.06

 Monocytes (× 10⁹/L)

0.6 (0.3- 0.9)

0.6 (0.3–0.9)

0.5 (0.3–0.8)

0.021